Sam Chun Dang Pharm. Co. Ltd (000250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) has a cash flow conversion efficiency ratio of -0.044x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-15.17 Billion ≈ $-10.28 Million USD) by net assets (₩343.90 Billion ≈ $233.05 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sam Chun Dang Pharm. Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 000250 total debt and obligations for a breakdown of total debt and financial obligations.
Sam Chun Dang Pharm. Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sam Chun Dang Pharm. Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hyundai Mipo Dockyard
KO:010620
|
0.085x |
|
Vipshop Holdings Limited
NYSE:VIPS
|
N/A |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
0.002x |
|
Zhejiang Hailiang Co Ltd
SHE:002203
|
0.065x |
|
BNP Paribas Bank Polska S.A.
WAR:BNP
|
-0.032x |
|
Innolux Corp
TW:3481
|
0.028x |
|
Gruma S.A.B. de C.V.
MX:GRUMAB
|
0.074x |
|
Shan Dong Sun Paper Industry Joint Stock Co Ltd
SHE:002078
|
0.048x |
Annual Cash Flow Conversion Efficiency for Sam Chun Dang Pharm. Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 000250 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩266.11 Billion ≈ $180.34 Million |
₩21.77 Billion ≈ $14.75 Million |
0.082x | +4.22% |
| 2023-12-31 | ₩298.46 Billion ≈ $202.26 Million |
₩23.43 Billion ≈ $15.88 Million |
0.078x | +2.70% |
| 2022-12-31 | ₩173.74 Billion ≈ $117.74 Million |
₩13.28 Billion ≈ $9.00 Million |
0.076x | +272.65% |
| 2021-12-31 | ₩174.09 Billion ≈ $117.98 Million |
₩-7.71 Billion ≈ $-5.22 Million |
-0.044x | -354.23% |
| 2020-12-31 | ₩186.63 Billion ≈ $126.47 Million |
₩3.25 Billion ≈ $2.20 Million |
0.017x | -91.02% |
| 2019-12-31 | ₩157.87 Billion ≈ $106.99 Million |
₩30.60 Billion ≈ $20.74 Million |
0.194x | +15.00% |
| 2018-12-31 | ₩148.52 Billion ≈ $100.65 Million |
₩25.03 Billion ≈ $16.97 Million |
0.169x | -8.68% |
| 2017-12-31 | ₩141.34 Billion ≈ $95.78 Million |
₩26.09 Billion ≈ $17.68 Million |
0.185x | +30.05% |
| 2016-12-31 | ₩125.17 Billion ≈ $84.82 Million |
₩17.76 Billion ≈ $12.04 Million |
0.142x | -6.45% |
| 2015-12-31 | ₩114.32 Billion ≈ $77.47 Million |
₩17.34 Billion ≈ $11.75 Million |
0.152x | +8.38% |
| 2014-12-31 | ₩139.68 Billion ≈ $94.66 Million |
₩19.55 Billion ≈ $13.25 Million |
0.140x | +4.69% |
| 2013-12-31 | ₩119.23 Billion ≈ $80.80 Million |
₩15.94 Billion ≈ $10.80 Million |
0.134x | +622.90% |
| 2012-12-31 | ₩86.63 Billion ≈ $58.71 Million |
₩1.60 Billion ≈ $1.09 Million |
0.018x | -- |
About Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more